1. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data (EMEA/CHMP/313666/2005). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf Consulté le 17 décembre 2013 (21 pages).
2. Méthodes d’évaluation des risques liés aux prises médicamenteuses pendant la grossesse. Avantages et limites de l’épidémiologie, interprétation des résultats;Robert-Gnansia;Therapie,2002
3. The Swedish medical birth register: a summary of content and quality;The national board of health and welfare,2003
4. Organization of teratology information services (OTIS): update and direction. In: NATO Advanced Research Workshop on “Drugs in Pregnancy: Consensus Conference on Teratogen Information Services”, Prague, 16–18 April 2004;Chambers;Reprod Toxicol,2004
5. Post-marketing surveillance system for drugs in pregnancy-15years experience of ENTIS;Schaefer;Reprod Toxicol,2005